Modeling the impact of peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin therapy on life expectancy and medical care costs in chronic hepatitis C.

被引：0

作者：

Jensen, CDM

Bernstein, DE

Hassanein, TI

Foster, GR

Lee, SS

Cheinquer, H

Craxi, A

Cooksley, WGE

Klaskala, W

Green, J

机构：

[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA

[2] N Shore Univ Hosp, Manhasset, NY USA

[3] Univ Calif San Diego, San Diego, CA 92103 USA

[4] Univ London Imperial Coll Sci Technol & Med, London, England

[5] Univ Calgary, Calgary, AB, Canada

[6] Univ Fed Rio Grande Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil

[7] Inst Clin Med Policlin, Palermo, Italy

[8] Royal Brisbane Hosp, Brisbane, Qld 4029, Australia

[9] Hoffmann La Roche Inc, Nutley, NJ 07110 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1761

引用

页码：603A / 603A

页数：1